
GNFT
Genfit
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
consensus rating "Strong Buy"
Hanging Man
Bearish Abandoned Baby
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About GNFT
Genfit S.A.
A late-stage biopharmaceutical company that develops therapeutic diagnostic solutions for metabolic liver-related diseases
Pharmaceutical
Invalid Date
03/27/2019
NASDAQ Stock Exchange
159
12-31
Depository Receipts (Ordinary Shares)
Parc Eurasante, 885, avenue Eugene Avinee, 59120 Loos, France
--
Genfit S.A. is a late-stage clinical biopharmaceutical company dedicated to the discovery and development of innovative drug candidates and diagnostic solutions for metabolic and liver-related diseases, where there are considerable unmet medical needs. They are leaders in nuclear receptor-based drug discovery with a rich history of nearly 20 years and a strong scientific legacy.
Company Financials
EPS
GNFT has released its 2022 Q2 earnings. EPS was reported at -0.23, versus the expected 0.00, missing expectations. The chart below visualizes how GNFT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available